JAZZ Q3 2017 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$412M+10.1% YoY

Gross Profit

$381M92.4% margin

Operating Income

$86M21.0% margin

Net Income

$64M15.4% margin

EPS (Diluted)

$1.03

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$189M

Free Cash Flow

$106M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$5.0B

Total Liabilities

$2.5B

Stockholders' Equity

$2.5B

Cash & Equivalents

$253M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$412M	$374M	+10.1%
Gross Profit	$381M	$350M	+8.8%
Operating Income	$86M	$136M	-36.5%
Net Income	$64M	$87M	-27.1%

Revenue Segments

Xyrem

$304M74%

Erwinaze And Erwinase

$49M12%

Defitelio

$31M8%

Vyxeos

$10M2%

Prialt

$8M2%

Other Products

$6M1%

Geographic Segments

UNITED STATES

$373M91%

Europe

$25M6%

Other Countries

$14M3%